elbasvir Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Elbasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural protein 5A (NS5A). Elbasvir was approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier. Zepatier is indicated for treatment of chronic HCV genotype 1 or 4 infection in adults.   NCATS

Chemistry

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C5=C4)C9=CC=CC=C9
  • InChIKey: BVAZQCUMNICBAQ-PZHYSIFUSA-N
  • Mol. Mass: 882.0171
  • ALogP: 8.12
  • ChEMBL Molecule:
    elbasvir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( elbasvir, grazoprevir (zepatier) )

Alternative names

2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1h-imidazol-2-yl)phenyl)benzofuran-5-yl)-1h-imidazole | elbasvir | elbasvir / grazoprevir | mk8742 | mk 8742 | mk-8742

Organizations (55)

Research & Development (55)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Hepatitis C, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Carcinoma, Hepatocellular (Phase 3)

Cardiovascular Diseases (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Cross Infection (Phase 4)

Deglutition Disorders (Phase 1)

Heart Transplantation (Phase 4)

Hepacivirus (Phase 2/Phase 3)

Hepatic Insufficiency (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic ()

Hepatitis, Viral, Human (Phase 1)

HIV (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 4)

Liver Cirrhosis (Phase 3)

Liver Transplantation (Phase 4)

Lung Diseases (Phase 1/Phase 2)

Metabolic Syndrome (Phase 3)

Renal Dialysis (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Substance Abuse, Intravenous (Phase 4)

Substance-Related Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial Organizations: 55

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue